Diabetes Care Journal (ADA): August, 2023Early identification of patients
with type 2 diabetes who are at risk of kidney disease progression is
particularly important in the context of new glucose-lowering medications such
as sodium-glucose cotransporter 2 (SGLT2) inhibitor (Dapagliflozin, Canagliflozin,
Empagliflozin, Ertugliflozin) that can m...